Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Forns

Showing results (111-120 of 298) with videos related to

Pageof 30
Sort By:
Journal of Hepatology|April 8, 2014
Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantationZoe Mariño, Laura Mensa, Gonzalo Crespo, et al.
Journal of Hepatology|December 3, 2014
Hepatitis C virus infection inhibits P-body granule formation in human liversGemma Pérez-Vilaró, Carlos Fernández-Carrillo, Laura Mensa, et al.
Plos One|September 3, 2011
Cell culture replication of a genotype 1b hepatitis C virus isolate cloned from a patient who underwent liver transplantationGeorge Koutsoudakis, Sofia Perez-del-Pulgar, Mairene Coto-Llerena, et al.
Journal of Hepatology|February 27, 2018
The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list compositionGonzalo Crespo, Núria Trota, Maria-Carlota Londoño, et al.
Plos One|January 12, 2016
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 StudiesHeiner Wedemeyer, Xavier Forns, Christophe Hézode, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 17, 2018
Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantationSabela Lens, María García-Eliz, Inmaculada Fernández, et al.
The Journal of General Virology|March 24, 2005
Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis CFrancesc Puig-Basagoiti, Xavier Forns, Ivana Furčić, et al.
Plos One|December 29, 2016
HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic ImpairmentChristoph Sarrazin, Michael Manns, Jose Luis Calleja, et al.
Plos One|January 10, 2013
Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteinsGeorge Koutsoudakis, Jakub Dragun, Sofia Pérez-Del-Pulgar, et al.
Medicine|March 18, 2003
Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 casesManuel Ramos-Casals, Mario García-Carrasco, Francisco López-Medrano, et al.
Pageof 30

Showing results (111-120 of 298) with videos related to

Sort By:
Pageof 30
Journal of Hepatology|April 8, 2014
Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantationZoe Mariño, Laura Mensa, Gonzalo Crespo, et al.
Journal of Hepatology|December 3, 2014
Hepatitis C virus infection inhibits P-body granule formation in human liversGemma Pérez-Vilaró, Carlos Fernández-Carrillo, Laura Mensa, et al.
Plos One|September 3, 2011
Cell culture replication of a genotype 1b hepatitis C virus isolate cloned from a patient who underwent liver transplantationGeorge Koutsoudakis, Sofia Perez-del-Pulgar, Mairene Coto-Llerena, et al.
Journal of Hepatology|February 27, 2018
The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list compositionGonzalo Crespo, Núria Trota, Maria-Carlota Londoño, et al.
Plos One|January 12, 2016
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 StudiesHeiner Wedemeyer, Xavier Forns, Christophe Hézode, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 17, 2018
Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantationSabela Lens, María García-Eliz, Inmaculada Fernández, et al.
The Journal of General Virology|March 24, 2005
Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis CFrancesc Puig-Basagoiti, Xavier Forns, Ivana Furčić, et al.
Plos One|December 29, 2016
HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic ImpairmentChristoph Sarrazin, Michael Manns, Jose Luis Calleja, et al.
Plos One|January 10, 2013
Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteinsGeorge Koutsoudakis, Jakub Dragun, Sofia Pérez-Del-Pulgar, et al.
Medicine|March 18, 2003
Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 casesManuel Ramos-Casals, Mario García-Carrasco, Francisco López-Medrano, et al.
Pageof 30